Literature DB >> 11884276

Purinergic signaling and vascular cell proliferation and death.

Geoffrey Burnstock1.   

Abstract

Evidence for the role of purinergic signaling (via P1 and P2Y receptors) in the proliferation of vascular smooth muscle and endothelial cells is reviewed. The involvement of the mitogen-activated protein kinase second-messenger cascade in this action is clearly implicated, although details of the precise intracellular pathways involved still remain to be determined. Synergistic actions of purines and pyrimidines with growth factors occur in promoting cell proliferation. Interaction between purinergic signaling for vascular cell proliferation and cell death mediated by P2X7 receptors is discussed. There is evidence of the release of ATP from endothelial cells, platelets, and sympathetic nerves as well as from damaged cells in atherosclerosis, hypertension, restenosis, and ischemia; furthermore, there is evidence that vascular smooth muscle and endothelial cells proliferate in these pathological conditions. Thus, the involvement of ATP and its breakdown product, adenosine, is implicated; it is hoped that with the development of selective P1 (A2) and P2Y receptor agonists and antagonists, new therapeutic strategies will be explored.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11884276     DOI: 10.1161/hq0302.105360

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  109 in total

1.  Discovery of purinergic signalling, the initial resistance and current explosion of interest.

Authors:  G Burnstock
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 2.  Extracellular adenosine: a safety signal that dampens hypoxia-induced inflammation during ischemia.

Authors:  Almut Grenz; Dirk Homann; Holger K Eltzschig
Journal:  Antioxid Redox Signal       Date:  2011-04-11       Impact factor: 8.401

Review 3.  Extracellular ATP and other nucleotides-ubiquitous triggers of intercellular messenger release.

Authors:  Herbert Zimmermann
Journal:  Purinergic Signal       Date:  2015-11-06       Impact factor: 3.765

4.  Purinergic signaling regulates neural progenitor cell expansion and neurogenesis.

Authors:  Jane H-C Lin; Takahiro Takano; Gregory Arcuino; Xiaohai Wang; Furong Hu; Zbigniew Darzynkiewicz; Marta Nunes; Steven A Goldman; Maiken Nedergaard
Journal:  Dev Biol       Date:  2006-09-16       Impact factor: 3.582

5.  Invited Lectures : Overviews Purinergic signalling: past, present and future.

Authors: 
Journal:  Purinergic Signal       Date:  2006-05-15       Impact factor: 3.765

Review 6.  Purinergic signalling in the kidney in health and disease.

Authors:  Geoffrey Burnstock; Louise C Evans; Matthew A Bailey
Journal:  Purinergic Signal       Date:  2013-11-22       Impact factor: 3.765

7.  S-nitrosylation inhibits pannexin 1 channel function.

Authors:  Alexander W Lohman; Janelle L Weaver; Marie Billaud; Joanna K Sandilos; Rachael Griffiths; Adam C Straub; Silvia Penuela; Norbert Leitinger; Dale W Laird; Douglas A Bayliss; Brant E Isakson
Journal:  J Biol Chem       Date:  2012-10-02       Impact factor: 5.157

8.  ATP and UTP responses of cultured rat aortic smooth muscle cells revisited: dominance of P2Y2 receptors.

Authors:  Rajendra Kumari; Gareth Goh; Leong L Ng; Michael R Boarder
Journal:  Br J Pharmacol       Date:  2003-11-03       Impact factor: 8.739

9.  Epithelial wounds induce differential phosphorylation changes in response to purinergic and EGF receptor activation.

Authors:  Amanuel Kehasse; Celeste B Rich; Albert Lee; Mark E McComb; Catherine E Costello; Vickery Trinkaus-Randall
Journal:  Am J Pathol       Date:  2013-10-01       Impact factor: 4.307

10.  Connexin hemichannels and gap junction channels are differentially influenced by lipopolysaccharide and basic fibroblast growth factor.

Authors:  Elke De Vuyst; Elke Decrock; Marijke De Bock; Hiroshi Yamasaki; Christian C Naus; W Howard Evans; Luc Leybaert
Journal:  Mol Biol Cell       Date:  2006-11-01       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.